Tempus AI Expands "Tempus Next" Platform to Improve Breast Cancer Care with AI-Driven Insights.

Tempus AI Inc. (NASDAQ:TEM) is one of the best young stocks to buy and hold for 5 years. On July 8, Tempus AI announced the expansion of its care pathway intelligence platform, called Tempus Next, to include breast cancer. Launched in 2024, Tempus Next has already screened thousands of patients and helped close critical care gaps for lung cancer patients across its network of provider sites.

The platform will now address 5 different biomarker testing gaps specific to breast cancer. Tempus Next assists physicians in providing guideline-based care by identifying care gaps and patients who could benefit from guideline-recommended suggestions. The platform integrates multimodal data from patients’ electronic medical records/EMR with up-to-date clinical guidelines.

Recognizing that breast cancer guidelines, much like those for lung cancer, are constantly evolving, Tempus is working to help providers stay current. Mercy, which is a healthcare system, has already integrated Tempus Next for both breast and lung cancer into its EMR system.

Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company.

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.